Horizon Orphan v. Teva: Cysteamine Patent Litigation Stayed Pending 2026 Regulatory Stay Expiration
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Horizon Orphan, LLC et al. v. Teva Pharmaceuticals, Inc. |
| Case Number | 1:22-cv-01382 (D.N.J.) |
| Court | U.S. District Court for the District of New Jersey |
| Duration | Mar 2022 – Feb 2025 3 years |
| Outcome | Administratively Terminated |
| Patents at Issue | |
| Accused Products | Teva’s generic PROCYSBI® (cysteamine bitartrate) Delayed-Release Capsules & Granules |
Case Overview
The Parties
⚖️ Plaintiffs
Biopharmaceutical company specializing in rare and rheumatic diseases, alongside the foundational IP licensor (The Regents of the University of California) for cysteamine technology.
🛡️ Defendant
One of the world’s largest generic drug manufacturers, seeking to market generic versions of PROCYSBI® before patent expiration.
The Patents at Issue
This case involves six U.S. patents protecting PROCYSBI® (cysteamine bitartrate) delayed-release formulations, covering both capsule and granule dosage forms:
- • US9173851B1 — Delayed-release cysteamine bitartrate compositions
- • US9233077B2 — Methods of treating cystinosis using delayed-release formulations
- • US8026284B2 — Enteric-coated pharmaceutical compositions
- • US9192590B2 — Methods and compositions for treating cystinosis
- • US10143665B2 — Oral delayed-release pharmaceutical compositions
- • US9198882B2 — Delayed-release cysteamine formulations for treating cystinosis
Developing a new drug formulation?
Check if your product might infringe these or related patents.
Litigation Timeline & Legal Analysis
Outcome
This case did not reach a merits verdict. The February 25, 2025 order constitutes an **administrative termination** — a procedural mechanism distinct from dismissal. Per *Papotto v. Hartford Life & Acc. Ins. Co.*, 731 F.3d 265, 275 (3d Cir. 2013), cited directly by the Court, administrative termination preserves the Court’s jurisdiction and leaves all substantive claims unresolved. No damages were awarded. No injunctive relief was granted or denied on the merits. The case remains legally alive, poised to resume once FDA regulatory stays expire in mid-2026.
Key Legal Developments
The complaint was filed on March 15, 2022, triggering the automatic 30-month regulatory stay under the Hatch-Waxman Act. A critical procedural development occurred on March 28, 2023, when the case was stayed at the joint request of both parties. On February 25, 2025, Chief Judge Renee Marie Bumb ordered administrative termination, noting that the 30-month regulatory stays cannot expire until **June and July 2026**. Citing *Dietz v. Bouldin*, 579 U.S. 40, 47 (2016), the Court invoked its inherent authority to manage docket efficiency. This signals that New Jersey district courts will not passively maintain open dockets solely because parties request stays.
Filing a new drug patent?
Learn from this case. Use AI to draft stronger claims that can withstand litigation.
Power Your Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical formulations. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all 6 asserted patents and their claims
- See the litigation history of these patents
- Understand implications for delayed-release formulations
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own drug formulation or product.
- Input your formulation details or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Cysteamine delayed-release formulations
6 Asserted Patents
In cysteamine formulation space
Strategic Options
Available for litigation management
✅ Key Takeaways
For Patent Attorneys
Administrative termination under *Papotto* preserves jurisdiction — it is not a dismissal and does not extinguish pending claims.
Search related case law →Hatch-Waxman 30-month stays can trigger judicial docket management actions independent of party requests.
Explore precedents →Multi-patent assertion strategies (six patents here) remain the gold standard in pharmaceutical infringement cases.
View Patent Portfolio →IPR petition windows remain open during district court stays — evaluate parallel PTAB strategy.
Run IPR Risk Assessment →For R&D Leaders
Layered pharmaceutical patent portfolios with diverse claim types (formulation, dosage, delivery) provide the strongest defense against generic entry.
Start FTO analysis for my product →Rare disease product developers should anticipate extended litigation timelines driven by regulatory — not just legal — calendars.
Try AI patent drafting →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.